Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: MPA Placebo Clear all
Completed Phase 2 Interventional Results available

Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis

NCT01399047
View directory record Official record
Conditions
Juvenile Neuronal Ceroid Lipofuscinosis
Interventions
Mycophenolate mofetil, Liquid Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
6 Years to 25 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2019 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Contraception and Menstrual Cycle Effect on Pharmacokinetics, Pharmacodynamics and Safety in Tenofovir Vaginal Gel Use

NCT01421368
View directory record Official record
Conditions
HIV Prevention
Interventions
Tenofovir 1% vaginal gel, Depo-medroxyprogesterone acetate (DMPA), Oral contraceptive: LNG 150 mcg and EE 30 mcg
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

NCT00594932
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritis
Interventions
mycophenolate mofetil, placebo
Drug · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
14 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT00430677
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Corticosteroids (prednisone or prednisolone), Abatacept, Mycophenolate mofetil (MMF)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Sep 6, 2026, 2:42 AM EDT
Active, not recruiting Phase 2 Interventional

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions
Iptacopan, Placebo, Rituximab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Mesa, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis

NCT01714817
View directory record Official record
Conditions
Lupus Nephritis
Interventions
BMS-188667, Mycophenolate mofetil, Prednisone, Placebo matching with BMS-188667
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
26
States / cities
Birmingham, Alabama • Long Beach, California • San Leandro, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial

NCT00100178
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Mycophenolate mofeteil (MMF), Daclizumab (DZB), Placebo control for Mycophenolate mofeteil (MMF), Placebo control for Daclizumab (DZB)
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients

NCT02991768
View directory record Official record
Conditions
Diarrhea
Interventions
Entocort, Placebos
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis

NCT00808132
View directory record Official record
Conditions
Menopause, Osteoporosis
Interventions
bazedoxifene 20 mg/ conjugated estrogens 0.45 mg, bazedoxifene 20 mg/ conjugated estrogens 0.625 mg, bazedoxifene 20 mg, conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 64 Years · Female only
Enrollment
1,886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
143
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)

NCT02383589
View directory record Official record
Conditions
Pemphigus Vulgaris
Interventions
Mycophenolate Mofetil Placebo, Mycophenolate Mofetil, Rituximab, Rituximab Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

NCT02028884
View directory record Official record
Conditions
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Interventions
Satralizumab, Placebo, Baseline Treatment
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years to 74 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 6, 2026, 2:42 AM EDT
Withdrawn Phase 2 Interventional

Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure

NCT00370019
View directory record Official record
Conditions
Premature Ovarian Failure
Interventions
Estradiol/Medroxyprogesterone acetate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

NCT01002742
View directory record Official record
Conditions
Graft-versus-Host Disease, Immune System Disorders
Interventions
Mycophenolate Mofetil, Placebo
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Not listed
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
36
States / cities
Duarte, California • La Jolla, California • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis

NCT02994927
View directory record Official record
Conditions
ANCA-Associated Vasculitis
Interventions
Avacopan, Prednisone, Cyclophosphamide, Rituximab, Azathioprine
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
41
States / cities
Huntsville, Alabama • Phoenix, Arizona • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

NCT02550652
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
7
States / cities
La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Sep 6, 2026, 2:42 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress

NCT02432339
View directory record Official record
Conditions
Psychological Stress, Hypertension, Renal
Interventions
mycophenolate mofetil (MMF), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

NCT05306873
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA

NCT03712345
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low dose, IFX-1 high dose, Placebo
Drug
Lead sponsor
InflaRx GmbH
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
33
States / cities
Scottsdale, Arizona • Loma Linda, California • Doral, Florida + 30 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Sep 6, 2026, 2:42 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 3 Interventional Results available

Belimumab in Remission of VASculitis

NCT01663623
View directory record Official record
Conditions
Vasculitis
Interventions
Placebo, Belimumab 10 mg/kg, Azathioprine
Biological · Drug
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 6, 2026, 2:42 AM EDT
Not listed Phase 2 Interventional

The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy

NCT02335203
View directory record Official record
Conditions
Grade 1 Endometrial Endometrioid Adenocarcinoma, Grade 2 Endometrial Endometrioid Adenocarcinoma, Complex Atypical Endometrial Hyperplasia
Interventions
Depot medroxyprogesterone acetate, Placebo
Drug · Other
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 4 Interventional

Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation

NCT00656266
View directory record Official record
Conditions
End-stage Liver Disease, Renal Insufficiency, Renal Failure
Interventions
mycophenolate mofetil, placebo medication
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 16 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Sep 6, 2026, 2:42 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation

NCT00048165
View directory record Official record
Conditions
Heart Transplantation
Interventions
Daclizumab, Methylprednisolone, Mycophenolate mofetil, Placebo, cyclosporine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Tampa, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 6, 2026, 2:42 AM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 6, 2026, 2:42 AM EDT